| Document |
Document Title |
|
WO/2005/042556A1 |
Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.
|
|
WO/2005/040184A1 |
A process is described for the preparation of doxifluridine of formula (I) at high yields and with reduced formation of impurities, which comprises the reaction of coupling of a compound of formula (III) with a compound of formula (IV), ...
|
|
WO/2005/039484A2 |
The present invention relates to anti-tumor compounds, compositions and methods. In particular, the invention relates to indolocarbazole analogues of general Formulas (I) and (II) that inhibit topoisomerase I activity.
|
|
WO/2005/040183A2 |
A description is given of a process for the preparation of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-phosphate starting from 9-beta-D-arabinofuranosyl-2-fluoroadenine by reaction with a mixture composed of triethyl phosphate and phosp...
|
|
WO/2005/040185A1 |
A method for producing a compound represented by the general formula (2) below is characterized in that a compound represented by the general formula (3) below is added when the compound represented by the general formula (1) below is re...
|
|
WO/2005/035545A2 |
Methods and probes are provided for the analysis of target sequences having two or more polymorphisms wherein one of the polymorphisms is to be distinguished and another polymorphism is to be masked.
|
|
WO/2005/034943A1 |
The present invention provides novel chemical compounds and methods for their use. In particular, the present invention provides indole derivatives (e.g. as shown in Formula (I)) and related compounds and methods of using indole derivati...
|
|
WO/2005/033121A2 |
Disclosed herein is a process for making aralkoxy- or alkoxyadenosines wherein a sugar protected haloadenosineis synthesized and the intermediate product is alkoxylated and then deprotected.
|
|
WO/2005/030997A1 |
The methods and apparatus disclosed herein concern nucleic acid characterization by enhanced Raman spectroscopy. In certain embodiments of the invention, exonuclease treatment of the nucleic acids results in the release of nucleotides. T...
|
|
WO/2005/028489A2 |
The invention realizes that a series of sulfonamido derivatives with a conserved uronamide group at the 5’ position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido deritatives ...
|
|
WO/2005/027838A2 |
Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided f...
|
|
WO/2005/028481A2 |
Disclosed are polycyclic polyether compounds of formula: (I) and pharmaceutical compositions comprising such compounds. Wherein R, OR1 and R2 are as defined herein. Also disclosed are methods of regulating mucus clearance in a cell, and ...
|
|
WO/2005/028494A1 |
A process in which nucleotide monomer synthesis and chain extension utilizing the synthesis can be easily conducted and problems in the H-phosphonate method are overcome. The process comprises reacting a nucleoside (2) with a phosphityla...
|
|
WO/2005/027962A2 |
The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least o...
|
|
WO/2005/026186A1 |
The invention relates to nucleoside analogues, nucleic acids and pharmaceutical agents comprising these, and to the use of the nucleoside analogues, nucleic acids and pharmaceutical agents for diagnosing, preventing or treating a viral, ...
|
|
WO/2005/026318A2 |
The present invention relates to methods of producing an antigenic response in which an antigen is contacted to an antigen-presenting cell, wherein the improvement comprises contacting the antigen-presenting cell with an A1 adenosine rec...
|
|
WO/2005/026187A1 |
A nucleoside, nucleotide, or derivative of either which has a nonnatural base. It is characterized by having as a base a 2-amino-6-(2-thiazolyl)purin-9-yl or 2-amino-6-(2-oxazolyl)purin-9-yl group (wherein the thiazolyl or oxazolyl group...
|
|
WO/2005/026188A1 |
A double-stranded oligonucleotide derivative which contains two oligonucleotide derivatives including at least one nucleotide derivative having been substituted at a nucleotide base part by a metal coordination group being hardly oxidize...
|
|
WO/2005/023826A2 |
The present invention relates to the polymorphic crystalline hydrochloride salts of a nucleoside valinate ester according to formula Ib, methods of treating diseases mediated by Hepatitis C Virus and pharmaceutical composition containing...
|
|
WO/2005/023829A1 |
It is intended to provide a novel structure in which metal atoms can be one-dimensionally aligned and which can exist in a stable state. Namely, a double-stranded oligonucleotide derivative which contains two oligonucleotide derivatives ...
|
|
WO/2005/023827A1 |
Process and novel intermediates for preparing 2-aminocarboxylic acid esters of the 5- hydroxymethyl group of levovirin (1-(3S, 4R-dihydroxy-5S-hydroxymethyl-tetrahydro furan-2S-yl)-IH-[1,2,4]triazole-3-carboxylic acid amide; Id: R1=R2 ...
|
|
WO/2005/021571A1 |
Disclosed is a method for producing a compound represented by the general formula (5) below wherein a compound represented by the general formula (1) below or a salt thereof is reacted with a dimethoxytrityl halide for isolating a compou...
|
|
WO/2005/021569A1 |
Described is a compound of the formula (I) wherein the bond between carbon atoms 22 and 23 is a single or double bond; m is 0 or 1; R1, is C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl; and either (A) R2 is -N(R3)R4, and (1) X is 0, wher...
|
|
WO/2005/020885A2 |
The present invention provides compositions and methods for treating a coronavirus infection, especially a SARS CoV infection, are presented. The compositions comprise an antiviral nucleoside or mimetic thereof, or an antiviral antisense...
|
|
WO/2005/021570A1 |
It is intended to provide oligonucleotide analogs usable in, for example, the antisense method which are highly tolerant to enzymes, have a strong and selective binding affinity for a single-stranded RNA and also are highly capable of fo...
|
|
WO/2005/021778A2 |
The invention provides methods and materials for conversion of cytosine to uracil. In some embodiments, a nucleic acid, such as gDNA, is reacted with bisulfite and a polyamine catalyst, such as a triamine or tetra-amine. Optionally, the ...
|
|
WO/2005/020884A2 |
This invention is in the area of methods and pharmaceutical compositions for treating a host, especially a human, infected with a coronavirus, togavirus or picornavirus, comprising administering to that host an effective amount of a comp...
|
|
WO/2005/016514A2 |
Methods are disclosed for providing a library of composite or novel composition samples on a support. The method involves depositing one or more components as concentration gradients on the surface of the support. The concentration gradi...
|
|
WO/2005/014609A2 |
To provide an efficient production method for a highly stereoregular phosphorus atom-modified nucleotide where a conformation on a phosphorus atom is controlled. A production method for a highly stereoregular phosphorus atom-modified nuc...
|
|
WO/2005/014610A1 |
A method of easily releasing a useful substance bonded to oligonucleotide without impairing a target nucleic acid; and a novel base therefor. A nucleoside or nucleotide (oligonucleotide containing the same) represented by the formula: (I...
|
|
WO/2005/012327A2 |
Phosphoramidate derivatives of nucleotides and their use in the treatment of cancer are described. The base moieties of, for example, each of deoxyuridine, cytarabine, gemcitabine and citidine may be substituted at the 5-position. The ph...
|
|
WO/2005/012323A2 |
Compounds useful as A3 Adenosine Receptor Agonists. Adenosine analogue-type A3 receptor agonists having an N6 substituent of the formula CR20R21CYCLE where CYCLE is a specified heterocycle, e.g. a substituted pyridyl group or a substitut...
|
|
WO/2005/011709A1 |
The present invention relates to novel compounds according to the general Formulae (I, II, III, IV or V); wherein B is nucleoside base according to the structure Formula (VI); R is H, F, Cl, Br, I, C1-C4 alkyl (preferably CH3), -C≡N, -...
|
|
WO/2005/012326A1 |
A compound of the formula (I) wherein Ring A and Ring B are: (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionall...
|
|
WO/2005/012325A1 |
A process for preparing 2',3'-didehydro-2',3'-dideoxynucleosides and 2',3'-dideoxynucleosides is described, which comprises the reductive elimination reaction of a compound of formula (I) in which X, Y, P' and B have the meanings given i...
|
|
WO/2005/009287A2 |
The inventors have demonstrated that they can deliver therapeutic compositions to the inner ear of mammals via a variety of routes including the round window membrane, the semicircular canals, via cochleostomy and through the stapes foot...
|
|
WO/2005/009418A2 |
This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofu...
|
|
WO/2005/005450A1 |
A compound represented by the general formula [2]: [2] (wherein R2 and R3 each independently represents hydrogen, halogeno, methoxy, 2-methoxyethoxy, or hydroxy; and B2 and B3 each independently represents a nucleic acid base) or a salt ...
|
|
WO/2005/003295A2 |
A method of stimulating in vivo or ex vivo maturation of dendritic cells by applying an effective amount of inosine-containing compounds to the dendritic cells. The maturation of dendritic cells leads to more robust cellular immune respo...
|
|
WO/2005/003374A2 |
An improved process for the preparation of 2'-modified nucleosides and 2'-deoxy-nucleosides, such as, β-L-2'-deoxy-thymidine (LdT), is provided. In particular, the improved process is directed to the synthesis of a 2'-deoxynucleoside th...
|
|
WO/2005/003147A2 |
The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially hum...
|
|
WO/2005/003291A2 |
The present invention includes composition and methods for making and using a combinatorial library having two or more beads, wherein attached to each bead is a unique nucleic acid aptamer that have disposed thereon a unique sequence. Th...
|
|
WO/2005/000204A2 |
N4 derivatives of the known antitumor compound CNDAC are useful in treatment of pancreatic cancer, especially as an adjuvant treatment and especially over long term administration.
|
|
WO/2005/000864A1 |
A process for the preparation of a 4’-azido-2’,3’,5’-triacyl-nucleoside compound (I;B=B1; R1 is R1aCO-and R2 is R2aCO-) or a 4’-azidonucleoside compounds (I; B is B1 or B2 and R1 and R2 are hydrogen and acid addition salts ther...
|
|
WO/2004/113553A2 |
The present invention relates to oligonucleotide synthesis. In particular, the present invention provides methods for making high quality phosphoramidites and oligonucleotides derived therefrom. In some embodiments, the methods comprise ...
|
|
WO/2004/113360A1 |
The invention relates to novel biologically active derivatives of 5'-phosphate 3'-azido-3'-deoxithymidine and of 2',3'-dideoxy-2',3'-didehydrothymidine and can be used in the form of antiviral agents, first and foremost against a human i...
|
|
WO/2004/111050A1 |
A process for producing an inosine derivative represented by the following general formula (1), which comprises dithiocarbonylating an inosine derivative represented by the following general formula (3) and reducing the resultant compoun...
|
|
WO/2004/111071A1 |
The invention relates to molecular biology, virology and medicine, namely to the use of novel derivatives of 2'3'-didezoxi-2'3'-didehydrothymidine (d4T)-aminocarbonyl-phosphonates of general formula (I), wherein R'=H, alkyl, aryl, R''=H,...
|
|
WO/2004/111079A1 |
The present invention provides the tertiary structure of a Hepatitis B Virus (HBV) polymerase reverse transcriptase (rt) domain from which a variant HBV polymerase mutations associated with resistance to or having reduced sensitivity to ...
|
|
WO/2004/111070A1 |
A compound of formula (I) wherein the bond between carbon atoms 22 and 23 may be a single or a double bond; R1 is C1-C12alkyl, C3-C8cycloalkyl, or C2-C12alkenyl; R2 and R3 are, for example, independently of each other hydrogen, C1-C12alk...
|
